InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.51
(
0.07%
)
US TECH 100
19,211.60
(
-0.02%
)
Dow Jones
39,122.62
(
-0.01%
)
Brent Oil
85.15
(
0.80%
)
Bitcoin
61,703.86
(
1.47%
)
Post# of 252398
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

flatlander_60048

Send PM Follow Ignore
Followers 10
Posts 476
Boards Moderated 0
Alias Born 02/10/2006

flatlander_60048

Re: None

Thursday, 06/10/2010 6:20:09 PM

Thursday, June 10, 2010 6:20:09 PM

Post# of 252398
FTY 720

Assuming FDA follows the recommendation within the expedited review period (next 2 months or so), which existing pharma stand to lose the most in the MS market:

A) Biogen
B) Teva
C) Elan
D) others

Even if the approval comes in the next couple of months, NVS owners should not gloat since there are already other oral MS drugs in late stage testing.

FL

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up